Cerus Corp is a biomedical company dedicated to improving blood safety. It specializes in the INTERCEPT Blood System, a technology aimed at reducing pathogens in blood components for transfusion. This system is applied to platelets, plasma, and red blood cells, aiming to make blood transfusions safer by inactivating blood-borne pathogens. Additionally, it offers a solution for producing pathogen-reduced fibrinogen complex, crucial for treating bleeding disorders. Cerus markets its products globally, serving healthcare providers in the U.S., Europe, and beyond, with a focus on enhancing transfusion safety and patient care.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
Here's a look at smaller cap companies that could very well offer patient investors some huge returns for the rest of 2023 and beyond.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
